Aspira Women’s Health Receives Approval from New York State Department of Health for OvaWatch®
New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State October 15, 2024 16:05 ET AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease…
Aspira Women’s Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass
The addition of miRNA and metadata to Aspira’s existing protein assay shows promising improvements in both sensitivity and specificity for early-stage ovarian cancer in women with an adnexal mass September 10, 2024 08:00 ET AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company…
Aspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 06, 2024 08:00 ET AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women’s Health will present at the H.C. Wainwright 26th Annual Global Investment…
Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub
“Spoke” designation acknowledges Aspira’s position as an innovator in women’s health, and provides new opportunities for funding, thought leadership and networking with other healthcare industry leaders September 05, 2024 08:00 ET AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the…
Aspira Women’s Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses
The innovative new tool will be made available for integration into Electronic Medical Records at over 300 clinical sites serving 2,500 clinical users August 27, 2024 08:00 ET AUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic…
Aspira Women’s Health Reports Second Quarter 2024 Financial Results
August 12, 2024 16:05 ET Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE)…
Aspira Women’s Health’s Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women’s Health (NPWH) Women’s Healthcare Conference
August 05, 2024 08:37 ET AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner’s in Women’s Health (NPWH) Woman’s Healthcare…
Aspira Women’s Health Announces Poster Presentation at the Menopause Society’s 2024 Annual Meeting
Presentation to highlight data demonstrating OvaWatch’s performance in assessing ovarian cancer risk in pre- and post-menopausal women August 01, 2024 08:00 ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a…
Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12
July 31, 2024 16:05 ET AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30,…
Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors
Mr. Ragard further strengthens the Board bringing more than 46 years of significant public equity investment and Wall Street experience July 29, 2024 09:00 ET AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools,…
Aspira Women’s Health Announces Preliminary Second Quarter 2024 OvaSuite Product Volume and Highlights
Preliminary OvaWatch® volume during Q2 2024 grew 24% over the prior quarter to 1,307 units Preliminary OvaSuiteSM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units AUSTIN, Texas, July 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused…
Aspira Women’s Health Announces Closing of $1.9 Million Private Placement Equity Financing
July 09, 2024 12:12 ET AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of…
Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing
July 01, 2024 17:24 ET AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing…
Aspira Women’s Health Provides Commercial, Reimbursement and Cash Guidance Updates
June 13, 2024 08:00 ET Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the…
Aspira Women’s Health to Present at the A.G.P. Healthcare Showcase on May 21
May 16, 2024 08:00 ET AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner’s Healthcare Showcase taking…
Aspira Women’s Health Reports First Quarter 2024 Financial Results
May 15, 2024 07:30 ET Q1 2024 OvaSuiteSM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc.…
Aspira Women’s Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
May 08, 2024 08:47 ET AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31,…
Aspira Women’s Health Announces Publication of Two OvaWatch Peer-Reviewed Manuscripts
May 07, 2024 08:00 ET AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts. The first manuscript, entitled “Ovarian Cancer Surgical Consideration is…
Aspira Women’s Health Enhances its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of OvaWatch
May 02, 2024 08:00 ET AUSTIN, Texas, May 02, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the formal launch of an updated OvaWatch ovarian cancer risk assessment test following the completion…
Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid April 09, 2024 08:00 ET AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a new agreement…
Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results
March 28, 2024 07:30 ET 2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am…
Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call
Management to Announce Earnings Results on Thursday, March 28, and hold a call at 8:30 am ET March 25, 2024 08:00 ET AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools,…
Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference
March 21, 2024 08:00 ET AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference…
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
March 18, 2024 08:00 ET Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors Aspira also announces Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team following the departure of Dr. Jody Berry AUSTIN, Texas,…
Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
March 11, 2024 08:00 ET AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended…